In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SunPharm Corp.

Division of Sanofi

Latest From SunPharm Corp.

US FDA Continues Reviewing Marketing Reports, Will It Punish Scofflaws?

Six months after submission deadline, about one-third of one-time marketing status reports have been reviewed, agency says.

Generic Drugs FDA

US FDA Continues Reviewing Marketing Reports, Will It Punish Scofflaws?

Six months after submission deadline, about one-third of one-time marketing status reports have been reviewed, agency says.

Generic Drugs FDA

Selected Start-Ups (10/00)

In Vivo summarizes the technologies of several recently founded companies: Spun out of London's Imperial College School of Medicine in July, Circassia Ltd. will develop treatments for cat-induced asthma and allergies. Copharos Inc., was formed in August 2000 to develop Vitamin B12-based radioactive imaging and therapeutic agents for the early detection and treatment of breast, lung and other cancers. EyeTech Pharmaceuticals Inc., founded in April 2000, has embarked on Phase IB trials for its drug for wet macular degeneration, a leading cause of adult-onset blindness. Invenux Inc. will use its Evolutionary Chemistry integrated discovery system to identify antibiotic compounds effective against drug-resistant organisms as well as discover drugs with broad-spectrum antibiotic activity. Sensatex/Lifelink Inc. will provide wireless, remote health care monitoring with its Smart Shirt, a special fabric interwoven with sensors that continuously relays information on a patient's vital signs. Sensory Technologies Inc. was formed in November 1999 to commercialize sensory-enhancement research of James Collins, PhD at Boston University's Center for Biodynamics.

Playing the High-Stakes Pharma Game, Part I

The rise in valuations of Big Biotech is due in large part to the fact that they're seen as affordable acquisition candidates for Big Pharmas in search of late-stage products. The plethora of early-stage biotech consolidation is, in contrast, generally a choice of last resort for otherwise unfinanceable companies who also can't sign worthwhile pharma deals. But the attention on late-stage programs offers opportunities for companies, like Pfizer, to strike platform technology deals which transfer technology, royalty free, from biotech to drug firm. The deals aren't cheap but these structures, impossible when platform deals were popular, allow Pfizer much greater research freedom.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sanofi
  • Senior Management
  • Stefan Borg, Pres. & CEO
    Paul M Herron, VP, CFO
    J. M Schafer, VP, Bus. Dev.
    James W Kesterson, PhD, VP, Product Dev.
  • Contact Info
  • SunPharm Corp.
    Phone: (904) 296-3320
    814 A1A North, #301
    Pointe Vedra Beach , FL 32082-3212
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register